Scientists solve puzzle of how kinesin motor molecules walk - or limp - across cells

December 05, 2003

Biophysicists at Stanford University have finally answered one of the most fundamental questions in molecular biology: How does the tiny motor molecule, known as kinesin, move across a living cell? According to the researchers, the solution to this longstanding problem will provide new insight into how motor proteins function, and may open new avenues of investigation for the treatment of cancer and various neurodegenerative diseases, such as Alzheimer's and Huntington's.

The study, published in the Dec. 4 online edition of the journal Science, was co-authored by Steven M. Block, a professor of applied physics and of biological sciences at Stanford.

"Motion at the cellular level is a hallmark of being alive," Block said. "A fundamental question is, how did living organisms figure out how to move? The answer is they developed kinesin and several other very efficient protein motors. If kinesin were to fail altogether, you wouldn't even make it to the embryo stage, because your cells wouldn't survive. It's that important."

Discovered in 1984, kinesin is now recognized as the workhorse of the cell, hauling chromosomes, neurotransmitters and other vital cargo along tiny molecular tracks called "microtubules." Many types of kinesin and kinesin-related proteins have been discovered in the past two decades in a wide range of organisms - from yeast to humans.

"Kinesin functions like a locomotive in cells to ferry cargo back and forth," Block said. "In brain cells, for example, it grabs these tiny sacs called vesicles, which are loaded with neurotransmitters that are needed for neurons to function, and moves them very long distances along microtubules."

A mere three-millionths of an inch long, a typical kinesin molecule has a tail on one end that hauls the cargo and two globular heads on the other end that alternately grab the microtubule and pull the cargo forward. One head has to be attached to the microtubule at all times for kinesin to advance against loads. "It's like pulling yourself straight up a ladder with your arms," Block explained. "If you were to let go of both hands, you'd fall off and that would be it."

Kinesin walking

For more than a decade, Block's lab and others have been trying to figure out the precise details of how kinesin's twin heads move - a process researchers call kinesin walking.

"There are two competing models for how kinesin walks: inchworm and hand-over-hand," Block said. "In the inchworm model, the leading head holds onto the microtubule, and the trailing head moves up to meet it. The second possibility is the hand-over-hand motion, which is more akin to the way we walk down the street, taking alternate strides every step."

In their experiment, Block and his colleagues used a specially designed microscope called the optical force clamp - a nanoscale instrument that allows researchers to watch a single kinesin molecule as it walks along a microtubule at rates up to about 100 steps per second. To their surprise, the researchers discovered that, instead of taking regular steps, kinesin actually walks with a limp.

"By 'limp' we mean that the timing of every alternate step is different than the one in between," Block said. "Suppose you have a sore leg that causes you to limp, and you have to walk across a river on stepping-stones, so you don't have any choice about where to put your feet. You don't want to spend a lot of time on the leg that's hurt, so you put it down and quickly get onto the other leg. As a result, the timing on every other step is short, whereas if you had two perfectly good legs, you'd spend equal time on each leg and your stride would be regular, not jerky."

This discovery provided an immediate solution to one part of the kinesin-walking puzzle.

"As soon as we saw limping, we said, 'Ah-hah!'," recalled Charles L. Asbury, a postdoctoral fellow in the Block lab and lead author of the Science study. "It's impossible for an inchworm to limp, because one head is always in the lead. Therefore kinesin must be using a hand-over-hand movement when it walks."

What's causing it to limp? "We're not sure," Block said, "but we speculate that maybe kinesin's coiled neck is getting over-wound and under-wound a little bit every time it takes a step."

Symmetry vs. asymmetry

The discovery of the hand-over-hand movement led the researchers to try and tackle another unanswered question: Is there symmetry in the way kinesin walks?

"It turns out that there are actually two kinds of the hand-over-hand models - asymmetric and symmetric," Block explained. "A normal human walk is asymmetric, because one leg always ends up in front of the other one, so at the end of each step, I'm in a different - that is, asymmetric - position relative to the axis of my body. In symmetric walking, I'm in the same geometry at the end of every step."

An example is a compass with a pencil on one arm that's used to mark off distances on a map. If you "walk" the compass in a line along a sheet of paper by rotating one arm in front of the other, the compass always ends up in the same symmetry after each step.

"But limping, by definition, means that every other step has to be different," he added. "That means kinesin's movements have to be asymmetric, so we can reject both the inchworm model and the symmetric hand-over-hand model."

Potential therapies

The kinesin-microtubule system has been implicated in several serious diseases, which is one reason why medical researchers are particularly interested in understanding the fine details of how kinesins walk across microtubules.

"A number of diseases - such as Huntington's and Alzheimer's - involve proteins glomming together in the cell in ways that they shouldn't," Block said. "The cell tries to get rid of these bad protein aggregates by transporting them elsewhere using motor molecules such as kinesin. If we could understand something about how protein transport is done right, then maybe we could learn something about how it's done wrong. It may be possible to develop therapies that block the kinsein motion and prevent bad things from happening. In the future, it may even be possible to develop less toxic therapies that target specific kinesins in cancer cells, without damaging the healthy ones."

For example, taxol, a drug commonly used to treat breast cancer, works by stabilizing the microtubules that kinesins walk along and preventing them from de-polymerizing, Block noted.

Recent studies also have shown that certain viruses, including smallpox and herpes, infect cells by hitching a ride on kinesin, added Adrian N. Fehr, a graduate student in applied physics at Stanford and co-author of the Science study. "Normally, kinesin moves cargo from one part of the cell to another," he said. "But certain viruses have chemical receptors that kinesin recognizes, which enables them to hijack the kinesin and get a free ride through the cell."
-end-
The study was funded by the National Institute of General Medical Sciences and Stanford University.

By Mark Shwartz

COMMENT: Steven Block, Departments of Biological Sciences and of Applied Physics: 650-724-4046, sblock@stanford.edu

EDITORS: The Dec. 4 study, "Kinesin Moves by an Asymmetric Hand-Over-Hand Mechanism," is available from the AAAS Office of Public Affairs: 202-326-6440, scipak@aaas.org. The abstract can be downloaded from the web at: http://scienceexpress.org. Images area available online at http://www.sciencemag.org.

Relevant Web URLs:
http://www.stanford.edu/group/blocklab/ScienceLimping
http://www.proweb.org/kinesin//index.html
Scientists solve puzzle of how kinesin motor molecules walk - or limp - across cells

News Service website: http://www.stanford.edu/news/
Stanford Report (university newspaper): http://news.stanford.edu Most recent news releases from Stanford: http://www.stanford.edu/dept/news/html/releases.html
To change contact information for these news releases: news-service@lists.stanford.edu
Phone: 650-723-2558

Stanford University

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.